The SARS-CoV-2 Spike (S) glycoprotein mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and, the C-terminal S2 subunit.
The SARS-CoV-2 Spike-Prot (HEK) protein covers the ectodomain of the viral surface protein including amino acids V16 to K1211 and contains the stabilizing proline substitutions at position K986P and V987P as well as a mutated

Data and images for Recombinant SARS-CoV-2 Spike-Prot (HEK)

Figures

Figure 1

View details
Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies
. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 1

Bead-based immunoassay for detection of patient-derived SARS-CoV-2 antibodies
. Schematic overview illustrating how our biotinylated antigens can be applied to detect patient-derived SARS-CoV-2 antibodies

Figure 2

View details
Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK).
The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19
+
patient (circle) or a healthy donor (square) are shown.

Figure 2

Results of the bead-based immunoassay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK).
The amount of captured SARS-CoV-2 antibodies was quantified at different plasma dilutions. Results for plasma from a COVID-19
+
patient (circle) or a healthy donor (square) are shown.

Figure 3

View details
Cell-based spike protein binding assay.
Schematic overview illustrating how our biotinylated spike proteins can be applied to analyze binding to ACE2-expressing cells.

Figure 3

Cell-based spike protein binding assay.
Schematic overview illustrating how our biotinylated spike proteins can be applied to analyze binding to ACE2-expressing cells.

Figure 4

View details
Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK).
ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated recombinant SARS-CoV-2 spike monomer (Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin).
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 4

Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK).
ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated recombinant SARS-CoV-2 spike monomer (Recombinant SARS-CoV-2 Spike-Prot (HEK)-Biotin).
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 5

View details
SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK)
under reduced (R) and non-reduced (NR) conditions.

Figure 5

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 Spike-Prot (HEK)
under reduced (R) and non-reduced (NR) conditions.

Specifications for Recombinant SARS-CoV-2 Spike-Prot (HEK)

Overview

The SARS-CoV-2 Spike (S) glycoprotein mediates the entry of the virus into target cells via its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, thereby initiating the infection. It forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and represents the major target for diagnostic and therapeutic agents. The ectodomain of the S glycoprotein comprises the N-terminal S1 subunit, including the receptor binding domain, and, the C-terminal S2 subunit.
The SARS-CoV-2 Spike-Prot (HEK) protein covers the ectodomain of the viral surface protein including amino acids V16 to K1211 and contains the stabilizing proline substitutions at position K986P and V987P as well as a mutated Furin cleavage site (RRAR to GSAS substitution at residues 682–685). The protein is extended at its C-terminus with a His-tag and an AviTagTM.

Resources for Recombinant SARS-CoV-2 Spike-Prot (HEK)

Related products for
Recombinant SARS-CoV-2 Spike-Prot (HEK)

8 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?